Not registered yet? Please contact our project manager Dr. Mary Gazea . This area is only for members of the research consortium.


25 October 2022

Opening of the 2022/2023 academic year of the Master in Bioethics and Law: Practical lecture on bioethical aspects in biomedical research projects funded by the European Union’s Horizon 2020 programme, taught by Itziar de Lecuona

The opening of the 2022/2023 academic year of the University of Barcelona’s Master in Bioethics and Law will take place on October 25, 2022.

Dr. Itziar de Lecuona, associate professor of the Department of Medicine, director of the Bioethics and Law Observatory and co-director of the Master in Bioethics and Law at the University of Barcelona, will give a practical lecture on bioethical aspects in biomedical research projects funded by the European Union’s Horizon 2020 programme.

This session will be held exclusively for new students of the Master in Bioethics and Law, and for researchers and doctoral students from the Bioethics and Law Observatory.

It will allow the attendees to identify which contributions they could provide from bioethics, based on their profile and knowledge, in the different phases of the project, within the framework of the respective Work Packages on “Ethics, Health and Socioeconomics”. It will intend to train and improve their skills in bioethics in the field of research ethics, scientific integrity and responsible research and innovation.

More information.

More news


19 - 21 October 2022

4th General Assembly (GA) meeting in Madrid

The 4th GA meeting of DECISION took place from 19-21 October 2022 in Madrid. The meeting was a great success with the first day devoted to paper writing: on that day, 12 meetings took place to discuss and progress on 7 different papers with more than 20 people. On the second day, we extensively discussed the specifics of our upcoming COMBAT-Trial as well as our brand new and refined animal models of ACLF. The third day was devoted to multi-omics analyses, bioinformatics and machine learning as well as an update on the newly developed tools and checklists for ethics and data protection and the health economics studies planned in DECISION. We thank our Scientific Advisory Board members for their valuable feedback to improve the quality of our studies.

More events

Our Vision

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop a reliable prognostic test and a robust response test.

Learn more

Why it matters

In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. While most cirrhosis patients initially do not show symptoms, acute decompensation of cirrhosis, defined as the body’s inability to cope with the progressing dysfunctionality of the liver, leads to drastic symptoms. Decompensation is characterized by the development of ascites, hepatic encephalopathy, jaundice, or gastrointestinal haemorrhage, and is often a turning point for cirrhosis.

Learn more